The effect of thio-TEPA on developing and established mammalian bladder tumors

W. M. Murphy, M. S. Soloway

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The inhibitory effect of thio-TEPA on both developing and established mammalian bladder cancer was tested in the FANFT model system using female C3H/He mice. This model allows the histologic evaluation of the entire target organ, a major advantage over clinical trials, which have relied largely on endoscopic appearance for determination of response. A powerful carcinogen, FANFT is known to cause bladder carcinoma in at least 90% of these animals within 12 months. The tumors develop through a spectrum of morphologic changes including hyperplasia, dysplasia, and carcinoma in situ. Animals were divided into equally sized control and test groups and either thio-TEPA or saline was administered on a schedule designed to correspond to that used in clinical trials. Bladders from 159 mice were evaluated grossly, microscopically and in some instances, ultrastructurally, for the presence of tumor or other intraepithelial lesions. When compared to controls, thio-TEPA had no statistically significant inhibitory effect on either developing or established bladder tumors. The drug did, however, cause a statistically significant decrease in the frequency of high-grade, high-stage lesions when given during tumor development and may retard the evolution of such neoplasms from low-grade noninvasive carcinomas. The correlation of these experimental findings with the reportedly beneficial results of clinical trials is discussed.

Original languageEnglish
Pages (from-to)870-875
Number of pages6
JournalCancer
Volume45
Issue number5
StatePublished - Jan 1 1980
Externally publishedYes

Fingerprint

Triethylenephosphoramide
Urinary Bladder Neoplasms
FANFT
Clinical Trials
Neoplasms
Urinary Bladder
Carcinoma
Inbred C3H Mouse
Carcinoma in Situ
Carcinogens
Hyperplasia
Appointments and Schedules
Control Groups
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Murphy, W. M., & Soloway, M. S. (1980). The effect of thio-TEPA on developing and established mammalian bladder tumors. Cancer, 45(5), 870-875.

The effect of thio-TEPA on developing and established mammalian bladder tumors. / Murphy, W. M.; Soloway, M. S.

In: Cancer, Vol. 45, No. 5, 01.01.1980, p. 870-875.

Research output: Contribution to journalArticle

Murphy, WM & Soloway, MS 1980, 'The effect of thio-TEPA on developing and established mammalian bladder tumors', Cancer, vol. 45, no. 5, pp. 870-875.
Murphy, W. M. ; Soloway, M. S. / The effect of thio-TEPA on developing and established mammalian bladder tumors. In: Cancer. 1980 ; Vol. 45, No. 5. pp. 870-875.
@article{762cfde2fda547c5bbe831fd399b5a8b,
title = "The effect of thio-TEPA on developing and established mammalian bladder tumors",
abstract = "The inhibitory effect of thio-TEPA on both developing and established mammalian bladder cancer was tested in the FANFT model system using female C3H/He mice. This model allows the histologic evaluation of the entire target organ, a major advantage over clinical trials, which have relied largely on endoscopic appearance for determination of response. A powerful carcinogen, FANFT is known to cause bladder carcinoma in at least 90{\%} of these animals within 12 months. The tumors develop through a spectrum of morphologic changes including hyperplasia, dysplasia, and carcinoma in situ. Animals were divided into equally sized control and test groups and either thio-TEPA or saline was administered on a schedule designed to correspond to that used in clinical trials. Bladders from 159 mice were evaluated grossly, microscopically and in some instances, ultrastructurally, for the presence of tumor or other intraepithelial lesions. When compared to controls, thio-TEPA had no statistically significant inhibitory effect on either developing or established bladder tumors. The drug did, however, cause a statistically significant decrease in the frequency of high-grade, high-stage lesions when given during tumor development and may retard the evolution of such neoplasms from low-grade noninvasive carcinomas. The correlation of these experimental findings with the reportedly beneficial results of clinical trials is discussed.",
author = "Murphy, {W. M.} and Soloway, {M. S.}",
year = "1980",
month = "1",
day = "1",
language = "English",
volume = "45",
pages = "870--875",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - The effect of thio-TEPA on developing and established mammalian bladder tumors

AU - Murphy, W. M.

AU - Soloway, M. S.

PY - 1980/1/1

Y1 - 1980/1/1

N2 - The inhibitory effect of thio-TEPA on both developing and established mammalian bladder cancer was tested in the FANFT model system using female C3H/He mice. This model allows the histologic evaluation of the entire target organ, a major advantage over clinical trials, which have relied largely on endoscopic appearance for determination of response. A powerful carcinogen, FANFT is known to cause bladder carcinoma in at least 90% of these animals within 12 months. The tumors develop through a spectrum of morphologic changes including hyperplasia, dysplasia, and carcinoma in situ. Animals were divided into equally sized control and test groups and either thio-TEPA or saline was administered on a schedule designed to correspond to that used in clinical trials. Bladders from 159 mice were evaluated grossly, microscopically and in some instances, ultrastructurally, for the presence of tumor or other intraepithelial lesions. When compared to controls, thio-TEPA had no statistically significant inhibitory effect on either developing or established bladder tumors. The drug did, however, cause a statistically significant decrease in the frequency of high-grade, high-stage lesions when given during tumor development and may retard the evolution of such neoplasms from low-grade noninvasive carcinomas. The correlation of these experimental findings with the reportedly beneficial results of clinical trials is discussed.

AB - The inhibitory effect of thio-TEPA on both developing and established mammalian bladder cancer was tested in the FANFT model system using female C3H/He mice. This model allows the histologic evaluation of the entire target organ, a major advantage over clinical trials, which have relied largely on endoscopic appearance for determination of response. A powerful carcinogen, FANFT is known to cause bladder carcinoma in at least 90% of these animals within 12 months. The tumors develop through a spectrum of morphologic changes including hyperplasia, dysplasia, and carcinoma in situ. Animals were divided into equally sized control and test groups and either thio-TEPA or saline was administered on a schedule designed to correspond to that used in clinical trials. Bladders from 159 mice were evaluated grossly, microscopically and in some instances, ultrastructurally, for the presence of tumor or other intraepithelial lesions. When compared to controls, thio-TEPA had no statistically significant inhibitory effect on either developing or established bladder tumors. The drug did, however, cause a statistically significant decrease in the frequency of high-grade, high-stage lesions when given during tumor development and may retard the evolution of such neoplasms from low-grade noninvasive carcinomas. The correlation of these experimental findings with the reportedly beneficial results of clinical trials is discussed.

UR - http://www.scopus.com/inward/record.url?scp=0018900975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018900975&partnerID=8YFLogxK

M3 - Article

C2 - 6790154

AN - SCOPUS:0018900975

VL - 45

SP - 870

EP - 875

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 5

ER -